Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™
An Observational Study to Investigate the Incidence of Influenza, Downstream Complications of Influenza and Hospitalizations, in Elderly Subjects Vaccinated With GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, 2606
- GSK Investigational Site
-
-
New South Wales
-
Umina, New South Wales, Australia, 2257
- GSK Investigational Site
-
-
Queensland
-
Auchenflower, Queensland, Australia, 4066
- GSK Investigational Site
-
Kippa Ring, Queensland, Australia, 4021
- GSK Investigational Site
-
South Brisbane, Queensland, Australia, 4101
- GSK Investigational Site
-
-
Tasmania
-
Hobart, Tasmania, Australia
- GSK Investigational Site
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- GSK Investigational Site
-
Heidelberg Heights, Victoria, Australia, 3084
- GSK Investigational Site
-
Parkville, Victoria, Australia, 3050
- GSK Investigational Site
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- GSK Investigational Site
-
-
-
-
-
São Paulo, Brazil, 04020050
- GSK Investigational Site
-
-
Paraná
-
Curitiba/Paraná, Paraná, Brazil, 80810-050
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
All subjects must satisfy to the following criteria at study entry:
- (1) A male or female age 65 years at the time of the first vaccination,
- (2) Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g., return for follow-up visits, disease reporting by phone, and completion of Questionnaires) should be enrolled in the study
- (3) Written informed consent obtained from the subject
- (4) Availability to follow up by phone during the study period
- (5) Subjects with residence status allowing free mixing with general community.
Exclusion Criteria
The subject must not be included in the study for:
- (1) history of hypersensitivity to a previous dose of influenza vaccine
- (2) history of allergy or reactions likely to be exacerbated by any component of the vaccine including egg, chicken protein, formaldehyde, thimerosal, gentamicin sulfate or sodium deoxycholate,
- (3) use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 106622
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Dataset Specification
Information identifier: 106622Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 106622Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 106622Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 106622Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 106622Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 106622Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.